FDA Extends Nexplanon Use - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Extends Nexplanon Use

US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.

  • By

  • Kathryn Wighton

  • January 20, 2026

  • 3 min

Share

  • 1

    The FDA approved extending Nexplanon's use from three years to five years based on clinical trial data.

  • 2

    The approval was supported by a study involving 399 women, showing no pregnancies during years 4 and 5.

  • 3

    No new safety findings were reported, and adverse reactions were consistent with the initial three years of use.

  • 4

    A Risk Evaluation and Mitigation Strategy (REMS) will be implemented to ensure proper insertion and removal.

  • 5

    Nexplanon is effective for pregnancy prevention but does not protect against HIV or other sexually transmitted diseases.

Original Source(s)

FDA Extends Nexplanon Use

  • by Kathryn Wighton

  • January 20, 2026

Related Content

Phthalates Linked to Shorter Gestation

Researchers linked several pregnancy urinary biomarkers—especially plasticizer and combustion-related chemical metabolites—to small shifts in gestational age and fetal growth measures in the ECHO Cohort.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Fertility Issues May Be Linked to Autism

In a nationwide US cohort, parental subfecundity was associated with higher odds of autism spectrum disorder and modest increases in behavioral symptoms, while in vitro fertilization showed no statistically significant associations with neurodevelopmental outcomes.